Furthermore, recent studies have shown the synergistic effect of ZOL and trametinib (MEK inhibitor) to inhibit growth and colony formation of MDA-MB-231 breast cancer cells [110], but also potentiate the antitumor activity in KRAS mutant tumors both in vitro and in vivo [111]. Here, KRAS is linked to breast cancer.